A Phase 2 Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies
Phase of Trial: Phase II
Latest Information Update: 07 Nov 2017
At a glance
- Drugs Niraparib (Primary)
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms GALAHAD
- Sponsors Janssen Research & Development
- 07 Nov 2017 According to a TESARO Inc. media release, data from this trial will support a planned regulatory submission in 2019.
- 27 Sep 2017 Planned End Date changed from 10 Oct 2019 to 31 Dec 2019.
- 10 Jun 2017 Biomarkers information updated